Cefecon N for adults, rectal 10 pcs

Cefecon N has analgesic, antipyretic and anti-inflammatory effects.

Naproxen and salicylamide are NSAIDs, whose mechanism of action is associated with inhibition of GH synthesis and influence on the thermoregulation center in the hypothalamus.

Caffeine has psychostimulant, analeptic and antispasmodic effect on smooth muscles, stimulates striated transverse muscles, reduces platelet aggregation and releases histamine from mast cells.

Indications

Cefekon N is prescribed as an analgesic for pain syndromes of varying severity:

sciatica;
toothache;
lumbago;
neuralgia;
migraine, headache;
degenerative-dystrophic diseases of the musculoskeletal system (ankylosing spondylitis, osteoarthritis, osteochondrosis);
myalgia;
primary algodismenorrhea.

As an antipyretic it is used for febrile syndrome during infectious, inflammatory or colds.

Pharmacological effect

Cefekon N has analgesic, antipyretic and anti-inflammatory effects.

Naproxen and salicylamide are NSAIDs, the mechanism of action of which is associated with inhibition of PG synthesis and an effect on the thermoregulatory center in the hypothalamus.

Caffeine has a psychostimulant, analeptic and antispasmodic effect on smooth muscle, stimulates striated muscle, reduces platelet aggregation and releases histamine from mast cells.

Special instructions

If itching or discomfort appears in the rectum, it is necessary to administer an enema with sunflower oil (1 tablespoon) and temporarily stop using the drug.

Active ingredient

Caffeine, Naproxen, Salicylamide

Composition

One suppository contains:

Active ingredients:

Caffeine – 50 mg,

Naproxen – 75 mg,

Salicylamide – 600 mg;

Excipients:

Solid fat (Vitepsol, brands H 15, W 35, Supposir, brands NA 15, NAS 50) – until a suppository weighing 2.20 g is obtained.

Contraindications

Cefekon N is not used in the following cases:

bleeding;
closed-angle glaucoma;
children under 16 years of age;
elderly people;
liver failure;
stomach ulcer;
hypersensitivity;
arterial hypertension;
insomnia;
duodenal ulcer;
renal failure;
pregnancy;
increased excitability;
diseases of the cardiovascular system;
breast-feeding;
bronchial obstruction;
chronic heart failure.

Side Effects

As a result of taking the drug, the following undesirable effects may develop:

melena, gastritis, constipation, stomatitis, vomiting, heartburn, hematemesis, esophagitis, ulcerative stomatitis, bleeding and ulcers in the gastrointestinal tract or perforation, exacerbation of Crohn’s disease or ulcerative colitis, flatulence, pancreatitis;
leukopenia, neutropenia, hemolytic anemia, eosinophilia, agranulocytosis;
anaphylactic reactions, bronchospasm, allergic reactions, angioedema;
hyperglycemia, hyperkalemia;
sleep disturbance, confusion, insomnia, depression, hallucinations;
cognitive disorders, convulsions, anxiety, aseptic meningitis, dizziness, tremor, difficulty concentrating, increased reflexes, paresthesia, headache, anxiety, optic neuritis;
corneal clouding, blurred vision, papilledema, papillitis;
hearing impairment;
edema, heart failure, chest pressure, arrhythmia;
vasculitis;
shortness of breath, pulmonary edema, nasal congestion, eosinophilic pneumonia;
hepatitis, increased liver enzymes, jaundice;
erythema multiforme, Steven-Johnson syndrome, rash, lichen planus, photosensitivity, pustular reactions, alopecia, itching, lupus erythematosus, bruising, erythema nodosum, purpura, epidermal necrolysis, urticaria, increased sweating;
muscle weakness, pain;
nephrotic syndrome, frequent urination, glomerulonephritis, hematuria, renal failure, interstitial nephritis, elevated creatinine levels, kidney necrosis (medullary);
female infertility;
fever, malaise, thirst, fatigue.

Interaction

Reduces the hypotensive effect of beta-blockers, ACE inhibitors; enhances the effect of anticoagulants, oral hypoglycemic agents – sulfonylurea derivatives.

Overdose

The hypotensive effect of ACE inhibitors and beta-blockers is reduced when taking Cefekon N.

When taken with sulfonylurea derivatives (oral hypoglycemic agents, anticoagulants), it enhances their effect.

Storage conditions

In a dry place, protected from light, at a temperature not exceeding 20 °C

Shelf life

2 years

Manufacturer

Nizhpharm JSC, Russia